The FDA has given mobocertinib expedited approval for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations

Share This Post

September 2021: The FDA granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion mutations, as detected by an FDA-approved test, and whose disease has progressed on or after platinum-based chemotherapy.

The Oncomine Dx Target Test (Life Technologies Corporation) was also approved by the FDA today as a companion diagnostic device for selecting patients with the aforesaid mutations for mobocertinib treatment.

Study 101, a non-randomized, open-label, multicohort clinical trial (NCT02716116) that included patients with locally advanced or metastatic NSCLC who had EGFR exon 20 insertion mutations, received FDA approval. The efficacy of 114 patients whose illness had worsened during or after platinum-based treatment was assessed. Patients were given mobocertinib 160 mg orally once a day until the disease progressed or effects became unbearable.

Overall response rate (ORR) according to RECIST 1.1 as assessed by blinded independent central review (BICR) and response duration were the key efficacy outcome measures. With a median response time of 17.5 months, the ORR was 28 percent (95 percent CI: 20 percent, 37 percent) (95 percent CI: 7.4, 20.3).

Diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, weariness, dry skin, and musculoskeletal pain were the most prevalent side effects (>20 percent). A boxed warning for QTc prolongation and Torsades de Pointes is included on the product label, as well as cautions for interstitial lung disease/pneumonitis, cardiac toxicity, and diarrhoea.

Until disease progression or severe toxicity, the recommended mobocertinib dose is 160 mg orally once daily.

Take second opinion on lung cancer treatment

Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy